OmniAb Competitors
| OABI Stock | USD 1.86 0.04 2.20% |
OmniAb vs Milestone Pharmaceuticals Correlation
Weak diversification
The correlation between OmniAb Inc and MIST is 0.33 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding OmniAb Inc and MIST in the same portfolio, assuming nothing else is changed.
Moving against OmniAb Stock
| 0.83 | ACLX | Arcellx | PairCorr |
| 0.77 | RANI | Rani Therapeutics | PairCorr |
| 0.75 | EVGN | Evogene | PairCorr |
| 0.75 | APLT | Applied Therapeutics | PairCorr |
| 0.63 | CRBP | Corbus Pharmaceuticals | PairCorr |
OmniAb Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between OmniAb and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of OmniAb and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of OmniAb Inc does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between OmniAb Stock performing well and OmniAb Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze OmniAb's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CDXS | 3.67 | (0.99) | 0.00 | (28.06) | 0.00 | 5.66 | 22.77 | |||
| SGMO | 4.28 | (0.10) | 0.00 | (0.01) | 0.00 | 8.51 | 21.63 | |||
| IVVD | 5.01 | (0.07) | 0.00 | (0.46) | 0.00 | 11.11 | 46.37 | |||
| IMDX | 3.94 | 0.10 | 0.02 | 0.52 | 4.55 | 9.03 | 22.08 | |||
| CCCC | 3.35 | (0.25) | 0.00 | (8.83) | 0.00 | 8.16 | 24.93 | |||
| RANI | 4.70 | (0.37) | 0.00 | (0.12) | 0.00 | 9.28 | 63.72 | |||
| IPHA | 2.52 | (0.31) | 0.00 | (1.46) | 0.00 | 3.41 | 39.49 | |||
| ARMP | 5.55 | 0.43 | 0.05 | (0.52) | 6.62 | 14.07 | 38.51 | |||
| TARA | 4.04 | 0.60 | 0.11 | 0.43 | 4.79 | 11.78 | 39.96 | |||
| MIST | 3.16 | 0.06 | 0.01 | 0.11 | 4.19 | 6.15 | 34.31 |
Cross Equities Net Income Analysis
Compare OmniAb Inc and related stocks such as Codexis, Sangamo Therapeutics, and Invivyd Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDXS | (18.7 M) | (16.6 M) | (30.9 M) | (41.3 M) | (19.1 M) | (7.6 M) | (8.6 M) | (23 M) | (10.9 M) | (11.9 M) | (24 M) | (21.3 M) | (33.6 M) | (76.2 M) | (65.3 M) | (58.7 M) | (55.8 M) |
| SGMO | (308 K) | (35.8 M) | (22.3 M) | (26.6 M) | (26.4 M) | (40.7 M) | (71.7 M) | (54.6 M) | (68.3 M) | (75.8 M) | (121.1 M) | (178.3 M) | (192.3 M) | (257.8 M) | (97.9 M) | (88.1 M) | (83.7 M) |
| IVVD | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (226.8 M) | (241.3 M) | (198.6 M) | (169.9 M) | (152.9 M) | (160.6 M) |
| IMDX | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (5 M) | (8.7 M) | (11.2 M) | (19.4 M) | (15.8 M) | (22.3 M) | (29.9 M) | (64.1 M) | (72.9 M) | (27.8 M) | (60.7 M) | (54.6 M) | (51.9 M) |
| CCCC | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (34.1 M) | (66.3 M) | (83.9 M) | (128.2 M) | (132.5 M) | (105.3 M) | (94.8 M) | (99.5 M) |
| RANI | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (16.7 M) | (8.3 M) | (30.6 M) | (34 M) | (30 M) | (27 M) | (28.4 M) |
| IPHA | (6.1 M) | (7 M) | (3.2 M) | (2.9 M) | (19.6 M) | (6.7 M) | 12.6 M | (48.4 M) | 3 M | (20.8 M) | (64 M) | (52.8 M) | (58.1 M) | (7.6 M) | (49.5 M) | (44.5 M) | (42.3 M) |
| ARMP | (5.1 M) | (3.8 M) | (1.1 M) | (64.6 M) | 23.1 M | (516 K) | (18.8 M) | (12.8 M) | (12.1 M) | (19.5 M) | (22.2 M) | (23.2 M) | (36.9 M) | (69 M) | (18.9 M) | (17 M) | (17.9 M) |
| TARA | (8 M) | (8 M) | (8 M) | (7.9 M) | (3.3 M) | (21.4 M) | (28.5 M) | (30 M) | (25.4 M) | (15 M) | (34 M) | (47.3 M) | (66 M) | (40.4 M) | (44.6 M) | (40.1 M) | (42.1 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.9 M) | (57.1 M) | (59.7 M) | (41.5 M) | (37.4 M) | (39.2 M) |
OmniAb Inc and related stocks such as Codexis, Sangamo Therapeutics, and Invivyd Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in OmniAb Inc financial statement analysis. It represents the amount of money remaining after all of OmniAb Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.OmniAb Competitive Analysis
The better you understand OmniAb competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, OmniAb's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across OmniAb's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
OmniAb Competition Performance Charts
Five steps to successful analysis of OmniAb Competition
OmniAb's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by OmniAb Inc in relation to its competition. OmniAb's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of OmniAb in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact OmniAb's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to OmniAb Inc, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your OmniAb position
In addition to having OmniAb in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Data Storage Thematic Idea Now
Data Storage
Companies making data storages or providing data storage services. The Data Storage theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Data Storage Theme or any other thematic opportunities.
| View All Next | Launch |
Check out OmniAb Correlation with its peers. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is there potential for Biotechnology market expansion? Will OmniAb introduce new products? Factors like these will boost the valuation of OmniAb. Anticipated expansion of OmniAb directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about OmniAb listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Revenue Per Share | Quarterly Revenue Growth (0.46) | Return On Assets | Return On Equity |
OmniAb Inc's market price often diverges from its book value, the accounting figure shown on OmniAb's balance sheet. Smart investors calculate OmniAb's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since OmniAb's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between OmniAb's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding OmniAb should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, OmniAb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.